A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed light beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. A treatment method for killing a tumor cell, the method including inserting a catheter into a main artery of an organ having the tumor cell, administering an antibody-photosensitive substance into a vein before the inserting of the catheter, inserting an optical fiber into the catheter, reducing an influence of blood in the artery on a near-infrared ray, irradiating at least one of a tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber, and irradiating an antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.

The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body. Here, the inventor(s) developed a system for emission of therapeutic doses of UV light via a catheter, capsule, endoscope, tube or port that can be used to manage internal infections and inflammatory conditions inside a patient.

Provided herein are methods and compositions for treating, mitigating, or preventing Parkinson's disease by administration of an anti-malassezial agent wherein the anti-malassezial agent is oteseconazole, tavaborole or 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

A light-emitting diode (LED) therapy device and method of use is provided that increases healing of tissues by targeting damaged tissue at a predetermined wavelength and pulsed at a predetermined frequency. The device includes a housing and a light radiation module enclosed within the housing. The light radiation module includes an LED, a controller unit connected to the LED to control wavelength and pulsed frequency of the LED, and a rechargeable power source. The device also includes a light-diffusing member connected to the housing designed to diffuse light emitted from the LED to damaged tissue in a human cavity. Light in the red or near infrared range and pulsed at a Nogier frequency increases the effectiveness of the LED device to stimulate healing of damaged tissues. Particular devices include incorporation into a pacifier for healing an infant's gums, or nasal, auditory, vaginal, or anal cavities and adults or children.

Systems, methods, and computer-readable media for enabling ultraviolet radiation treatments are provided.

An irradiation device for insertion into an orifice of the body to provide photodynamic therapy comprises: a housing moulded from a resilient material and adapted to be fully inserted and secured in the orifice, the housing enclosing an LED lamp system 22 and a power source 41 for powering the LED lamp system 22; wherein the device is independently operational while located in the orifice; characterized in that: the housing comprises a first housing part 2 for holding the power source 41 and a second housing part 4 for holding the LED lamp system 22, the first and second housing parts 2, 4 being separable and being preferably formed separately from the LED lamp system 22; and in that the first housing part 2 consists of a chamber 6 for holding the power source 41 and an opening 26 into the chamber 6 is provided through a resilient opening part 8, wherein the chamber 6 is closed when the first housing part 2 is joined to the second housing part 4.

A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed light beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.